Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Vaccine Study for High Risk Cancers

This study has been terminated.
(unexpectedly low screening results leading to poor accrual)
Information provided by:
Penn State University Identifier:
First received: July 21, 2009
Last updated: July 26, 2011
Last verified: August 2010

The purpose of this study is to determine the safety and immunological effects of a vaccine for people diagnosed with high risk neuroblastoma, osteogenic sarcoma, and rhabdomyosarcoma. It is hypothesized that this vaccine could reduce the incidence of relapse.

Condition Intervention Phase
Osteogenic Sarcoma
Biological: MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Study to Determine the Immunologic Effects of a MAGE- A1, MAGE- A3, NY-ESO-1 Vaccine in Patients With High Risk Neuroblastoma, Osteogenic Sarcoma, and Rhabdomyosarcoma

Resource links provided by NLM:

Further study details as provided by Penn State University:

Primary Outcome Measures:
  • The primary objective is to determine if there is an amplification or new development of NY-ESO-1, MAGE-A1, or MAGE-A3 specific CD4+ or CD8+ T cells post-vaccination. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The investigators will determine the safety of vaccine and imiquimod administration in these patients. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Enrollment: 0
Study Start Date: June 2009
Study Completion Date: August 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine
    A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
Detailed Description:

MAGE -A1, MAGE- A3, and NY-ESO-1 are antigens that can be found with significant frequency on neuroblastoma, rhabdomyosarcoma, and osteogenic sarcoma, three relatively common solid tumors that in some cases can be associated with a high risk for relapse. In this study each subject will be screened for the presence of these antigens, and an individualized vaccine will be developed and administered using the subject's own dendritic cells (DC).

This study consists of two phases: a screening phase and a treatment/vaccine phase. First, eligible individuals will be consented into the screening phase. Tumor specimens will be tested by immunohistochemistry or RT-PCR for the presence of MAGE- A1, MAGE- A3, and NY-ESO-1. Those testing positive for one or more antigen can be consented for the treatment phase of the study. Blood will be drawn for DC culture, and approximately one month later a series of three vaccines will be administered at two week intervals. Subjects will receive a topical medication called imiquimod to the vaccine site prior to and following each injection, to help immune cells travel into the area. Study participation occurs over 18 months and also involves periodic physical examinations and blood draws.


Ages Eligible for Study:   1 Year to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria for Screening Phase:

Patient 1 to 70 years of age with neuroblastoma, rhabdomyosarcoma, or osteogenic sarcoma, who have one or more of the following high risk features:

  • Neuroblastoma:

    • Stage IV disease
    • Stage III disease with n-myc amplification
  • Osteogenic sarcoma:

    • Presence of metastases
    • Elevated alkaline phosphatase or LDH at diagnosis
    • Primary tumor affecting the axial skeleton
    • Poor histopathological response after completion of pre-surgical chemotherapy (≥10% viable tumor)
  • Rhabdomyosarcoma:

    • Stage IV disease
    • Alveolar histology
    • Positive tumor margins, with lymph node positivity

Inclusion Criteria for Vaccine Phase:

  • Patient meets all screening criteria and tumor is positive for NY-ESO-1, MAGE- A1, or MAGE-A3 by immunohistochemistry or RT-PCR.
  • Patients who are between 3 months and 2 years following the completion of therapy, and have achieved at least a very good partial response to primary therapy.
  • No chemotherapy is planned for one month following the last vaccination.
  • Bilirubin <2 mg/dL, and SGOT/SGPT <2.5 x normal
  • Creatinine clearance > 50ml/min as estimated by patient's serum creatinine, weight, and age
  • Room air pulse oximetry >94%
  • Patient is not pregnant
  • Male and female sexually active patients of reproductive who wish to participate must agree to use acceptable contraception
  • Patient is not moribund and has a projected life expectancy >6 months
  • Lansky performance scale > 70, ECOG < 2 (Appendix I)
  • Potential subjects will be tested for HIV 1 and 2 antibodies, HTLV 1/2 antibodies, and for HIV 1, hepatitis C and hepatitis B virus by NAT testing. - -Subjects testing positive for any of these pathogens will be ineligible for vaccine.
  • White blood cells ≥ 2.5 K/µL, Hemoglobin ≥ 8 g/dL, Hematocrit > 25%, and Platelets ≥ 70 K/µL
  • Patient does not have central nervous system involvement.
  • Patient does not a have a history of autoimmune disease, specifically inflammatory bowel disease, systemic lupus erythematosis, or rheumatoid arthritis
  • Patient is not receiving concurrent systemic steroid therapy
  • Patient does not have a known systemic hypersensitivity to imiquimod or any vaccine component
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00944580

Sponsors and Collaborators
Penn State University
Study Chair: Kenneth G. Lucas, MD Milton S. Hershey Medical Center
  More Information

No publications provided

Responsible Party: Kenneth G. Lucas, MD, Penn State University Identifier: NCT00944580     History of Changes
Other Study ID Numbers: IRB 30761, PSHCI 09-033
Study First Received: July 21, 2009
Last Updated: July 26, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Penn State University:
dendritic cells

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Muscle Tissue
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral processed this record on November 20, 2014